Statin use significantly improves overall survival in high-grade endometrial cancer

Abstract

predictors, and impact of chemotherapy and radiation on survival in women diagnosed with UCCC. Methods: The Surveillance, Epidemiology and End Results (SEER) — Medicare database was used to identify women diagnosed with UCCC from1992 to 2009. Standard univariate analyses and multivariable analyses with logistic regression were performed. Kaplan– Meier survival analysis was used to generate overall survival (OS) data. Factors predictive of outcomes were compared using the logrank test and Cox proportional hazards model. Results: A total of 468 patients met eligibility criteria; 50% of women presented with stage I disease, 11.5% with stage II, 14.5% with stage III, and 21.3% with stage IV. The majority of patients (82.8%) underwent definitive surgery. Chemotherapy, radiation, and chemotherapy combined with radiation were administered in 16.5%, 32.5%, and 13.2% of women; 37.8% of women did not receive adjuvant therapy. Utilization of chemotherapy became more frequent over time across all stages. After adjusting for race, period of diagnosis, marital status, stage, age, surgery, lymph node dissection, socioeconomic status, and comorbidity index, there was no association between receipt of chemotherapy (HR 0.7; 95% CI, 0.4–1.1; P = 0.2), combination of chemotherapy and radiation (HR 0.9; 95% CI, 0.5–1.5; P = 0.7), or radiation (HR 0.9; 95% CI, 0.6–1.4; P= 0.9) and improved survival. There was no improvement in survival over the study period. Conclusions: The overall rates of chemotherapy utilization have increased over time in patients with UCCC. Chemotherapy, radiation, and the combination of chemotherapy and radiation were not associated with increased survival.